Loading…
← CockpitCompetitor Analysis › 600085.SS Beijing TongRenTang Co., Ltd. Class AOpen in the cockpit ↗

Beijing TongRenTang Co., Ltd. Class A600085.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

China's most prestigious traditional-Chinese-medicine (TCM) brand, making and retailing TCM products through its own pharmacy chain.

≈ A Chinese CVS crossed with a heritage herbal-medicine brandMomentum leader 80
Mkt cap
$4.91B
US dollars, full cap
Free float
46%
of shares outstanding
$/day
$32.1M
20-day average traded
Fwd P/E
28.7×
forward earnings
ROIC−WACC
+1.3 pp
WACC 5.6%
Hurdle
-5 pp
Req g minus delivered
Next earnings
132 days
30 Mar 2027
Close · CNYCN¥23.90
1D-0.9%
1W-1.8%
1M-4.3%
3M-3.8%
6M-12.4%
YTD-25.9%
1Y-28.6%
ATR %2.2%
52w lowhigh33.4% off high

What Beijing TongRenTang does

China's most prestigious traditional-Chinese-medicine (TCM) brand, making and retailing TCM products through its own pharmacy chain.

Makes patent medicines to long-standing recipes, sold through hospitals, other pharmacies and its own stores, so it captures both factory and retail margin on part of its sales. Herbal ingredients are its main costs. State-owned China Beijing Tongrentang Group is the controlling shareholder.

In one line: A Chinese CVS crossed with a heritage herbal-medicine brand.

Products and services

  • TCM patent medicines
  • Retail pharmacy chain
  • Health/wellness products

Customers

  • Patients/consumers via hospitals and its pharmacy

Where it sits in the supply chain

  • Health Care
  • Traditional Chinese medicine
  • TCM manufacturing + retail pharmacies

What could go right

  • TCM demand growth, incl. overseas Chinese communities

What could go wrong

  • TCM efficacy/regulatory scrutiny
  • Centralized procurement price pressure

Moat: narrow (brand). Nearly 350-year-old heritage brand with strong consumer trust in TCM, though products are largely undifferentiated compounds.

Headquarters: Beijing, China · Founded: 1669 · Employees: 17,284

Named competitors

Beijing TongRenTang at a glance

Size Beijing TongRenTang (600085.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $4.91B, the 474th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥23.90 on 18 Nov 2026.

Performance Over six months the shares fell 12.4%, against +10.6% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 21 in its peer set.

Growth Revenue fell 17.0% over the last twelve months (peer median +13.1%); the operating margin is 7.7% (peer median 20.6%).

Valuation It trades at 28.7× forward earnings against a peer median of 25.8× (9th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -5 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.3 points above its cost of capital (5.6% WACC).

Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026Peer median 112600085.SS 91
Six months, rebased to 100: Beijing TongRenTang against the median of its 20 peers (local-currency closes).

Beijing TongRenTang financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥15.0BCN¥17.2BCN¥18.5BCN¥17.7BCN¥15.3B
Revenue growth—-7%+4%+16%—
Gross profitCN¥6.38BCN¥6.48BCN¥7.34BCN¥7.65BCN¥6.69B
EBITDAn/aCN¥2.98BCN¥3.64BCN¥3.90BCN¥3.58B
Net incomeCN¥878MCN¥1.19BCN¥1.53BCN¥1.67BCN¥1.43B
Free cash flowCN¥2.27BCN¥2.34BCN¥362MCN¥1.79BCN¥2.88B
Capital expenditureCN¥316MCN¥357MCN¥520MCN¥325MCN¥330M
Total debtCN¥3.65BCN¥4.21BCN¥4.74BCN¥3.43BCN¥3.02B

Quarterly statements and history in the cockpit →

Beijing TongRenTang competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%0%+20%600079ERASTVTXIPCALABPTCT326030GLAXOLQDAEMCUREMANEIONS6885780874AJANTPHARM600566CAMX603087002294GLAND600085.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Beijing TongRenTang is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%+600%+800%20×40×600079TVTXIPCALABPTCT326030GLAXOLQDAEMCURE68857845060874CAMX603087002294GLAND600085.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Beijing TongRenTang is the large dot.

Capital: growth delivered against growth the price implies

0%+200%+400%0%200%400%600079TVTXPTCT326030LQDA688578600085.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Beijing TongRenTang is the large dot.

Beijing TongRenTang competitors and peer comparison

Head to head with its named competitors (600085.SS vs 000999.SZ vs 000538.SZ vs 600436.SS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Beijing TongRenTang 600085.SS$4.91B-12%-17%8%28.7×1.7%
China Resources Sanjiu Medical & Pharmaceutical 000999.SZ$6.59B+6%+4%14%13.2×-6.2%
Yunnan Baiyao 000538.SZ$15.0B+11%+5%11%18.3×-0.2%
Zhangzhou Pientzehuang Pharmaceutical 600436.SS$11.6B-4%-19%19%40.7×24.9%
Tasly Pharmaceutical 600535.SS$3.19B-2%-4%19%16.7×-7.5%
Dong-E-E-Jiao 000423.SZ$4.99B+1%+8%29%17.8×-3.7%
Shijiazhuang Yiling Pharmaceutical 002603.SZ$3.83B-7%+32%21%17.5×-3.9%
Jiuzhitang 000989.SZ$1.16B-7%+46%19%22.1×-4.0%

How Beijing TongRenTang compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Beijing TongRenTang against its 20 peers (data as of 18 Nov 2026)
Measure600085.SSPeer medianRank in peer set
1-month return-4.3%+0.2%7th lowest of 21
6-month return-12.4%+10.6%7th lowest of 21
Distance from 52-week high-33.4%-24.4%10th lowest of 21
Revenue growth (TTM)-17.0%+13.1%2nd lowest of 19
Operating margin7.7%20.6%4th lowest of 19
Forward P/E28.7×25.8×9th most expensive of 18
Growth the price implies (Req g, 7 yrs)1.7%7.3%6th least demanding of 17
Growth delivered (Del g)+6.2%+13.0%6th lowest of 17
Hurdle (Req g minus delivered)-4.5 pp-2.6 pp8th least demanding of 17
ROIC minus cost of capital+1.3 pp+4.6 pp5th lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Beijing TongRenTang 600085.SSChina$4.91B-12%-17%8%28.7×1.7%+6.2%
Humanwell Healthcare (Group) 600079.SSChina$4.87B+11%+2%15%13.8×-8.8%+3.0%
Erasca ERASUnited States$4.83B+24%n/an/an/an/an/a
Travere Therapeutics TVTXUnited States$4.82B+16%+49%-3%17.1×17.3%+19.9%
IPCA Laboratories IPCALAB.NSIndia$5.03B+12%+12%18%31.1×16.5%+12.2%
PTC Therapeutics PTCTUnited States$5.03B-15%-35%22%31.2×6.6%+35.4%
SKBP 326030.KSSouth Korea$5.03B-16%+37%38%21.5×-4.4%+93.6%
GlaxoSmithKline Pharmaceuticals GLAXO.NSIndia$4.79B+10%+12%33%37.3×26.4%+5.5%
Liquidia LQDAUnited States$5.08B-9%+798%47%13.8×5.0%+192.5%
Emcure Pharmaceuticals EMCURE.NSIndia$4.74B+37%+21%16%33.6×15.9%+12.7%
Veradermics MANEUnited States$5.27B+19%n/an/an/an/an/a
Ionis Pharmaceuticals IONSUnited States$4.56B-64%-1%-59%n/an/an/a
Shanghai Allist Pharmaceuticals 688578.SSChina$5.32B-14%+39%47%12.4×0.1%+519.6%
Sumitomo Pharma 4506.TJapan$5.33B+11%+11%10%8.6×1.7%-2.6%
Guangzhou Baiyunshan Pharmaceutical 0874.HKHong Kong$4.48B-23%+6%3%7.0×1.3%+4.0%
Ajanta Pharma AJANTPHARM.NSIndia$4.38B+1%+25%25%31.7×23.8%+13.8%
HUBEI JUMPCAN PHARMACEUTICAL 600566.SSChina$4.36B+12%-4%32%16.2×-9.9%+0.3%
Camurus CAMX.STSweden$4.36B+36%+3%38%45.1×7.9%+46.5%
Gan & Lee Pharmaceuticals 603087.SSChina$5.59B+11%+14%20%25.8×n/an/a
Shenzhen Salubris Pharmaceuticals 002294.SZChina$4.31B-24%+14%11%35.4×12.4%+9.7%
Gland Pharma GLAND.NSIndia$5.71B+44%+22%21%39.3×20.2%+13.3%

Questions

Who are Beijing TongRenTang's main competitors?
Named competitors: China Resources Sanjiu Medical & Pharmaceutical (000999.SZ), Yunnan Baiyao Group (000538.SZ), Zhangzhou Pientzehuang (600436.SS), Tasly Pharmaceutical (600535.SS), Shandong Dong-E E-Jiao (000423.SZ), Shijiazhuang Yiling Pharmaceutical (002603.SZ). The cockpit's measured peer set (industry) also includes Humanwell Healthcare (Group) (600079.SS), Erasca (ERAS), Travere Therapeutics (TVTX), IPCA Laboratories (IPCALAB.NS), PTC Therapeutics (PTCT), SKBP (326030.KS).
Is Beijing TongRenTang expensive compared with its peers?
On forward p/e it trades at 28.7× against a peer median of 25.8×, 9th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -5 pp: the price already allows for a slowdown.
How has Beijing TongRenTang stock performed?
Over six months to 18 Nov 2026 the shares returned -12.4% against +10.6% for the median peer; over one year -28.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.